4CPS-157 Vedolizumab: early experience and medium-term outcomes in inflammatory bowel disease

BACKGROUND: Vedolizumab is a monoclonal antibody approved for the treatment of moderate to severe inflammatory bowel disease (IBD) for those patients who have had inadequate or loss of response or were intolerant to a tumour necrosis factor alpha inhibitor (anti-TNF-alpha). PURPOSE: To assess prescr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Hosp Pharm
Auteurs principaux: Nieto, L Pedraza, Caballero, R Fernández, Sánchez-Hernández, JG, Rebollo, N, Pérez, MC Piñero, González, D García, Fernández, EM Sáez, López, MJ Otero
Format: Artigo
Langue:Inglês
Publié: BMJ Group 2018
Sujets:
Section 4: Clinical pharmacy services
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535236/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.248
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires